WO2016025401A1 - Oral composition for delivery of drugs and other substances - Google Patents

Oral composition for delivery of drugs and other substances Download PDF

Info

Publication number
WO2016025401A1
WO2016025401A1 PCT/US2015/044501 US2015044501W WO2016025401A1 WO 2016025401 A1 WO2016025401 A1 WO 2016025401A1 US 2015044501 W US2015044501 W US 2015044501W WO 2016025401 A1 WO2016025401 A1 WO 2016025401A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
general formula
carbon chain
agent
monoglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/044501
Other languages
English (en)
French (fr)
Inventor
Walter Shaw
Stephen W. Burgess
Shengrong LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanti Polar Lipids Inc
Original Assignee
Avanti Polar Lipids Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES15832041T priority Critical patent/ES3033965T3/es
Priority to KR1020227016492A priority patent/KR102507657B1/ko
Priority to JP2017527546A priority patent/JP6759203B2/ja
Priority to DK15832041.6T priority patent/DK3177279T3/da
Priority to AU2015301952A priority patent/AU2015301952B2/en
Priority to EP15832041.6A priority patent/EP3177279B1/en
Priority to CA2956960A priority patent/CA2956960C/en
Priority to KR1020177006233A priority patent/KR20170033442A/ko
Priority to CN201580049486.0A priority patent/CN107072967B/zh
Application filed by Avanti Polar Lipids Inc filed Critical Avanti Polar Lipids Inc
Publication of WO2016025401A1 publication Critical patent/WO2016025401A1/en
Priority to IL250394A priority patent/IL250394B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the delivery of active agents, such as therapeutics, to the body can be problematic.
  • active agents such as therapeutics
  • the amount of the agents that reaches the systemic circulation can be much less than the dose administered.
  • orally delivered drugs often have poor bioavailability due to a variety of factors (for example, poor solubility in the gut, degradation and the like). Many attempts to circumvent this problem have been attempted.
  • the art remains in need of improved compositions for the oral delivery of agents.
  • the present disclosure provides a novel composition for superior solublization of active agents and for formulating active agents for oral administration.
  • the present disclosure provides a composition for the solublization of agents.
  • the present disclosure also provides a composition for the oral delivery of agents.
  • the present disclosure provides for a composition
  • a composition comprising an agent, a lysophosphatidyl compound and at least one of a monoglyceride and a free fatty acid.
  • the composition comprises a lysophosphatidyl compound of the formula I and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I and at least one of a monoglyceride of the general formula IV A, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula II and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula II and at least one of a monoglyceride of the general formula IVA., a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula II and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula III and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula III and at least one of a monoglyceride of the general formula IVA, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula III and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula I, at least one lysophosphatidyl compound of the formula II or III, and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I, at least one lysophosphatidyl compound of the formula II or III, and at least one of a monoglyceride of the general formula IVA, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I, at least one lysophosphatidyl compound of the formula II or III, and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula I J, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IID, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IIIC, a monoglyceride of the general formula IVC and a free fatty acid of the general formula V A.
  • the composition is in the form of a eutectic.
  • the composition is useful for solubilizing an agent.
  • the agent is one that exhibits poor aqueous solubility.
  • the agent is one at which the dose strength required for treatment of a subject is not soluble in 100 ml of aqueous solution over a pH range of 1 to 7.
  • the agent is one at which the dose strength required for treatment of a subject is not soluble in 250 ml of aqueous solution over a pH range of 1 to 7.
  • the agent is a BCS class II or IV agent.
  • the compounds is a BCS class III compound.
  • the composition further comprises an agent, wherein the agent is solubilized in the composition.
  • the composition and the agent form a eutectic.
  • the agent is one that exhibits poor aqueous solubility.
  • the agent is one at which the dose strength required for treatment of a subject is not soluble in 100 ml of aqueous solution over a pH range of 1 to 7.
  • the agent is one at which the dose strength required for treatment of a subject is not soluble in 250 ml of aqueous solution over a pH range of 1 to 7.
  • the agent is a BCS class II or IV agent.
  • the compounds is a BCS class III compound.
  • the composition further comprises an agent and the composition is used for oral delivery of the agent to a subject.
  • the composition and the agent form a eutectic.
  • the agent is one that exhibits poor aqueous solubility.
  • the agent is one at which the dose strength required for treatment of a subject is not soluble in 100 ml of aqueous solution over a pH range of 1 to 7.
  • the agent is one at which the dose strength required for treatment of a subject is not soluble in 250 ml of aqueous solution over a pH range of 1 to 7.
  • the agent is a BCS class II or IV agent.
  • the compounds is a BCS class III compound.
  • FIG. 1 shows differential scanning calorimetry of a sample of curcumin.
  • FIG. 2 shows differential scanning calorimetry of a lipid mixture comprising lysophosphatidylglycerol (14:0), monoglyceride (14:0) and fatty acid (14:0).
  • FIG. 3 shows differential scanning calorimetry of a mixture of curcumin and a lipid mixture comprising lysophosphatidylglycerol (14:0), monoglyceride (14:0) and fatty acid (14:0).
  • FIG. 4 shows differential scanning calorimetry of a lipid mixture comprising lysophosphatidylcholine (14:0), monoglyceride (14:0) and fatty acid (14:0).
  • FIG. 5 shows differential scanning calorimetry of a mixture of curcumin and a lipid mixture comprising lysophosphatidylcholine (14:0), monoglyceride (14:0) and fatty acid (14:0).
  • the present disclosure provides a composition suitable for solubilizing an agent comprising a lysophosphatidyl compound of the general formula I, II or III, a monoglyceride of the formula IV and a free fatty acid of the formula V.
  • the lysophosphatidyl compound has the general formula I: wherein,
  • R] is a saturated or unsaturated carbon chain
  • R 2 is H, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkene, substituted or unsubstituted alkyne or an amino acid moeity; and,
  • Linker is a linking portion.
  • Ri is a saturated or unsaturated carbon chain.
  • Ri is a saturated carbon chain.
  • Ri is an unsaturated carbon chain; when R ⁇ is an unsaturated carbon chain, the carbon chain may contain from 1 to 6, from 1 to
  • Ri is an unsaturated carbon chain; containing from 1 to 6, from 1 to 4 or from 1 to 3 double bonds.
  • unsaturated carbon chains may be present in the cis or trans configuration, or a mixture of cis and trans configuration.
  • Ri is a carbon chain up to 5 carbons in length, a carbon chain from 6 to 12 carbons in length, a carbon chain from 13-21 carbons in length and a carbon chain greater than 22 carbons in length.
  • Ri is a carbon chain from 13 to 21 carbons in length.
  • Such carbon chain regardless of the length, includes both even and odd chain lengths and may be saturated or unsaturated; in one embodiment, the carbon chain is saturated.
  • i is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13,
  • Ri is a carbon chain of 3, 4, 5, 6, 7, 8, 9,
  • Rj is a carbon chain of 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated.
  • R] is a carbon chain of 12, 13, 14, 15 or 16, carbons, which are saturated or unsaturated, in another embodiment, Rj is a carbon chain of 13 carbons, which is saturated.
  • Non-limiting exemplary lysophosphatidyl compounds for use with the present invention include lauroyl-lysophosphatidyl compounds, myristoyllysophosphatidyl compounds, palmitoyl-lysophosphatidyl compounds, stearoyl-lysophosphatidyl compounds, arachidoyl-lysophosphatidyl compounds, oleoyl-lysophosphatidyl compounds, linoleoyllysophosphatidyl compounds, linolenoyl-lysophosphatidyl compounds and erucoyl lysophosphatidyl compounds.
  • R 2 is a substituted alkyl chain. In one embodiment, R 2 is a substituted alkyl chain from 1 to 10 carbons. In one embodiment, R 2 is a substituted alkyl chain, for example a substituted alkyl chain from 1 to 10 carbons, wherein the alkyl chain is substituted by one or more, 1 to 5 or 1 to 2 hydroxy groups, substituted N groups or NH 3 groups. In a particular embodiment, the substituted N group is substituted by 1 to 3 C1-C6 alkyl groups.
  • R 2 is -(CH 2 ) 2 -(N)(CH 3 ) 3 , -CH 2 -CH(OH)-CH 2 -CH(OH) or (CH 2 )2-NH 3 .
  • R 2 does not contain a N group.
  • R 2 is not -(CH 2 ) 2 -(N)(CH 3 ) 3 .
  • the linker is a non-immunogenic, hydrophilic polymer.
  • Representative hydrophilic polymers include, but are not limited to, linear or branched poly(dextran), linear or branched poly(cellulose), linear and branched poly(ethylene glycol), linear and branched poly(alkylene oxide), linear and branched poly(vinyl pyrrolidone), linear and branched poly(vinyl alcohol), linear and branched polyoxazoline, linear and branched poly(acryloylmorpholine), and derivatives thereof.
  • the linker is linear poly(ethylene glycol).
  • the repeating units of the polymer may vary from 1 to 50, more particularly from 1 to 25, from 1 to 15, from 1 to 8 or from 1-3.
  • the linker is a glycerol moiety or a substituted or unsubstituted alkyl chain and the lysophosphatidyl compound has a structure of the general formula I A or IB.
  • R] and R 2 are as defined above and n is from 1 to 20, 1 to 10 or 1 to 6.
  • n is 1 to 6 1 to 4 or 1 to 2 and the alkyl chain is an unsubstituted alkyl chain.
  • the lysophosphatidyl compound is a lysophosphatidylglycerol.
  • the lysophosphatidylglycerol is l-myristoyl-2-hydroxy-i , -glycero-3- phospho-(l '-rac-glycerol).
  • Representative lysophosphatidylglycerol compounds include those shown below IC to IE, wherein R] and n are as defined above.
  • i is a saturated carbon chain of 13 carbons in length.
  • the lysophosphatidyl compound has the structure IJ:
  • the lysophosphatidyl compound is a lysophosphatidylcholine.
  • the lysophosphatidylcholine is l-myristoyl-2-hydroxy- ⁇ «-glycero-3- phosphocholine.
  • Representative lysophosphatidylcholine compounds include those shown below IF and IH, wherein Ri and n are as defined above.
  • Ri is a saturated carbon chain of 13 carbons in length and the compound has the structure IK
  • the lysophosphatidyl compound has the general formula II:
  • R 2 is as defined above in the general formula I; R 1 1 is a saturated or unsaturated carbon chain; and Linker is a linking portion.
  • Rn is a saturated or unsaturated carbon chain.
  • Ri i is a saturated carbon chain.
  • Rj i is an unsaturated carbon chain; when R] i is an unsaturated carbon chain, the carbon chain may contain from 1 to 6, from 1 to 4 or from 1 to 3 double or triple bonds.
  • Ri i is an unsaturated carbon chain; containing from 1 to 6, from 1 to 4 or from 1 to 3 double bonds.
  • Such unsaturated carbon chains may be present in the cis or trans configuration, or a mixture of cis and trans configuration.
  • Ru is a carbon chain up to 5 carbons in length, a carbon chain from 6 to 12 carbons in length, a carbon chain from 13-21 carbons in length and a carbon chain greater than 22 carbons in length.
  • Rj j is a carbon chain from 13 to 21 carbons in length.
  • Such carbon chain regardless of the length, includes both even and odd chain lengths and may be saturated or unsaturated; in one embodiment, the carbon chain is saturated.
  • Rn is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 or more carbons, which are saturated or unsaturated.
  • Ri i is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated.
  • Rn is a carbon chain of 10, 11, 12, 13, 14, 15, 16, 17, 1 , 19, 20 or 21 carbons, which are saturated or unsaturated.
  • Rn is a carbon chain of 12, 13, 14, 15 or 16, carbons, which are saturated or unsaturated.
  • n is a carbon chain of 14 carbons, which is saturated.
  • the linker is a non-immunogenic, hydrophilic polymer.
  • Representative hydrophilic polymers include, but are not limited to, linear or branched poly(dextran), linear or branched poly(cellulose), linear and branched poly(ethylene glycol), linear and branched poly(alkylene oxide), linear and branched poly(vinyl pyrrolidone), linear and branched poly(vinyl alcohol), linear and branched polyoxazoline, linear and branched poly(acryloylmorpholine), and derivatives thereof.
  • the linker is linear poly(ethylene glycol).
  • the repeating units of the polymer may vary from 1 to 50, more particularly from 1 to 25, from 1 to 15, from 1 to 8 or from 1 to 3.
  • the linker is an alkyl chain and the lysophosphatidyl compound has a structure of the general formula IIA.
  • Rn and R 2 are as defined above and n is from 1 to 20, 1 to 10 or 1 to 6.
  • n is 1 to 6. 1 to 4 or 1 to 2.
  • Compounds of the formula IIA have the advantage that the lysophosphatidyl compounds are not hydrolyzable or are resistant to being hydrolyzed (when compared to compounds of the general formula I) when administered to subjects, including human subjects.
  • Representative lysophosphatidyl compounds represented by the general structure IIA include those shown below as IIB and IIC, wherein Ri ⁇ and n are as defined above.
  • Ri is a saturated carbon chain of 14 carbons in length and the compound has the structure IID or HE:
  • the lysophosphatidyl compound has the general formula III:
  • R 2 is as defined above in the general formula I; and Rio is a saturated or unsaturated carbon chain.
  • Rio is a saturated or unsaturated carbon chain.
  • Rio is a saturated carbon chain.
  • Rio is a an unsaturated carbon chain; when Rio is an unsaturated carbon chain, the carbon chain may contain from 1 to 6, from 1 to 4 or from 1 to 3 double or triple bonds.
  • Rio is a an unsaturated carbon chain; containing from 1 to 6, from 1 to 4 or from 1 to 3 double bonds.
  • Such unsaturated carbon chains may be present in the cis or trans configuration, or a mixture of cis and trans configuration.
  • Rio is a carbon chain up to 5 carbons in length, a carbon chain from 6 to 12 carbons in length, a carbon chain from 13-21 carbons in length and a carbon chain greater than 22 carbons in length.
  • Rio is a carbon chain from 13 to 21 carbons in length.
  • Such carbon chain regardless of the length, includes both even and odd chain lengths and may be saturated or unsaturated; in one embodiment, the carbon chain is saturated.
  • io is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or more carbons, which are saturated or unsaturated.
  • R 10 is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated.
  • Rio is a carbon chain of 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated.
  • R] 0 is a carbon chain of 12, 13, 14, 15 or 16 carbons, which are saturated or unsaturated.
  • R 10 is a carbon chain of 14 carbons, which is saturated.
  • IIIA Representative lysophosphatidyl compounds represented by the general structure III include those shown below IIIA and IIIB, wherein Rjo is as defined above.
  • IIIA Representative lysophosphatidyl compounds represented by the general structure III include those shown below IIIA and IIIB, wherein Rjo is as defined above.
  • Rio is a saturated carbon chain of 14 carbons in length and the compound has the structure IIIC or HID:
  • Monoglycerides are composed of a glycerol molecule wherein the glycerol molecule has formed an ester bond with exactly one fatty acid molecule.
  • Monoglycerides are also referred to as acyl glycerol and monoacyl glycerol.
  • Monoglycerides for use in the present disclosure have the general formula IV:
  • R4 is -C(0)-R 7 and the remaining are each independently selected from H or R 8 , wherein R 7 is a saturated or unsaturated carbon chain and R 8 is saturated or unsaturated carbon chain from 1 to 10 carbons in length.
  • R 7 is a saturated or unsaturated carbon chain.
  • R 7 is a saturated carbon chain.
  • R 7 is an unsaturated carbon chain; when. R 7 is an unsaturated carbon chain, the carbon chain may contain from 1 to 6, from 1 to 4 or from 1 to 3 double or triple bonds.
  • R 7 is an unsaturated carbon chain; containing from 1 to 6, from 1 to 4 or from 1 to 3 double bonds.
  • Such unsaturated carbon chains may be present in the cis or trans configuration, or a mixture of cis and trans configuration.
  • R 7 is a carbon chain up to 5 carbons in length, a carbon chain from 6 to 12 carbons in length, a carbon chain from 13-21 carbons in length and a carbon chain greater than 22 carbons in length.
  • R 7 is a carbon chain from 13 to 21 carbons in length.
  • Such carbon chain regardless of the length, includes both even and odd chain lengths and may be saturated or unsaturated; in one embodiment, the carbon chain is saturated.
  • R 7 is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or more carbons, which are saturated or unsaturated.
  • R is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated.
  • R 7 is a carbon chain of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated.
  • R 7 is a carbon chain of 12, 13, 14, 15 or 16, carbons, which are saturated or unsaturated.
  • R is a carbon chain of 13 carbons, which is saturated.
  • one of R 4 , R 5 and R 6 is -C(0)-R 7 and the remaining are H. In one embodiment, one of R 4 , R 5 and R 6 is -C(0)-R 7 and the remaining are independently H or saturated carbon chain from 1 to 4 or 1 to 2 carbons in length.
  • a monoacylglycerol is either a 1 -monoacylglycerol or a 2-monoacylglycerol, depending on the position of the ester bond on the glycerol moiety.
  • the monoglyceride is a 1 -monoacylglycerol.
  • Representative 1 -monoacylglycerols and 2- monoacylglycerols are shown below having the general formula IVA and IVB respectively, wherein R 7 is as defined above.
  • R 7 is a saturated carbon chain of 13 carbons in length.
  • the monoglyceride compound has the structure IVC.
  • Non-limiting exemplary monoglyceride compounds for use with the present invention include, but are not limited to, monoglycerides in which the esterified fatty acid is lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, stearidonic acid, vaccenic acid, linoleic acid, linoelaidic acid, ⁇ -linolenic acid and a-linolenic acid.
  • the esterified fatty acid is lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, stearidonic acid,
  • R 9 is a saturated or unsaturated carbon chain.
  • R 9 is a saturated or unsaturated carbon chain.
  • R 9 is a saturated carbon chain.
  • R 9 is a an unsaturated carbon chain; when R 9 is an unsaturated carbon chain, the carbon chain may contain from 1 to 6, from 1 to 4 or from 1 to 3 double or triple bonds.
  • R 9 is a an unsaturated carbon chain; containing from 1 to 6, from 1 to 4 or from 1 to 3 double bonds.
  • Such unsaturated carbon chains may be present in the cis or trans configuration, or a mixture of cis and trans configuration.
  • R9 is a carbon chain up to 5 carbons in length, a carbon chain from 6 to 12 carbons in length, a carbon chain from 13-21 carbons in length and a carbon chain greater than 22 carbons in length.
  • R9 is a carbon chain from 13 to 21 carbons in length.
  • Such carbon chain regardless of the length, includes both even and odd chain lengths and may be saturated or unsaturated; in one embodiment, the carbon chain is saturated.
  • 9 is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or more carbons, which are saturated or unsaturated.
  • R9 is a carbon chain of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated. In another embodiment, R9 is a carbon chain of 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 carbons, which are saturated or unsaturated. In another embodiment, R9 is a carbon chain of 12, 13, 14, 15 or 16, carbons, which are saturated or unsaturated. In another embodiment, R9 is a carbon chain of 13 carbons, which is saturated.
  • R 9 is a saturated carbon chain of 13 carbons in length.
  • the fatty acid compound has the structure VA.
  • Non-limiting exemplary free fatty acids for use with the present disclosure include, but are not limited to, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, stearidonic acid, vaccenic acid, linoleic acid, linoelaidic acid, ⁇ -linolenic acid and a-linolenic acid.
  • compositions in first embodiment, the composition comprises a lysophosphatidyl compound of the formula I and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I and at least one of a monoglyceride of the general formula IVA, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the lysophosphatidyl compound of the formula I may be a compound of the formula IA or IB or a combination of the foregoing.
  • the lysophosphatidyl compound of the formula I may be a compound of the formula IC, ID, IE, IJ, or a combination of the foregoing.
  • the lysophosphatidyl compound of the formula I may be a compound of the formula IF, IG, IH, IK or a combination of the foregoing.
  • the lysophosphatidyl compound of the formula I may be a compound of the formula IC, ID, IE, IJ, IF, IG, IH, IK or a combination of the foregoing. Further, in the foregoing first through third embodiments, the lysophosphatidyl compound of the formula I may be a compound of the formula IC, ID, IE, IJ, IH or a combination of the foregoing. Still further, in the foregoing first through third embodiments, the lysophosphatidyl compound of the formula I may be a compound of the formula IJ.
  • the composition comprises, a lysophosphatidyl compound, a monoglycende and a free fatty acid.
  • the alkyl chain of the lysophosphatidyl compound (Ri) is of an equal length as the alkyl chains of the free fatty acid (R 9 ) and monoglycende (one of R4, R 5 and R 6 ).
  • the composition comprises a lysophosphatidyl compound of the formula II and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula II and at least one of a monoglyceride of the general formula IVA, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula II and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the lysophosphatidyl compound of the formula II may be a compound of the formula IIA. Further, in the foregoing fourth through sixth embodiments, the lysophosphatidyl compound of the formula II may be a compound of the formula IIB, IIC or a combination of the foregoing. Still further, in the foregoing fourth through sixth embodiments, the lysophosphatidyl compound of the formula
  • the composition II may be a compound of the formula IID or HE. Still further, in the foregoing fourth through sixth embodiments, the lysophosphatidyl compound of the formula II may be a compound of the formula IID. Still further, in the foregoing fourth through sixth embodiments, the lysophosphatidyl compound of the formula II may be a compound of the formula HE. In the foregoing fourth through sixth embodiments, the composition comprises a lysophosphatidyl compound, a monoglyceride and a free fatty acid.
  • the alkyl chain of the lysophosphatidyl compound (Rn) is of an equal length as the alkyl chains of the free fatty acid (R 9 ) and monoglyceride (one of R4, R5 and R 6 ).
  • the composition comprises a lysophosphatidyl compound of the formula III and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula III and at least one of a monoglyceride of the general formula IVA, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula III and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the lysophosphatidyl compound of the formula III may be a compound of the formula IIIA, IIIB or a combination of the foregoing. Further, in the foregoing seventh through ninth embodiments, the lysophosphatidyl compound of the formula III may be a compound of the formula IIIC or HID. Further, in the foregoing seventh through ninth embodiments, the lysophosphatidyl compound of the formula III may be a compound of the formula IIIC. Further, in the foregoing seventh through ninth embodiments, the lysophosphatidyl compound of the formula III may be a compound of the formula HID.
  • the composition comprises a lysophosphatidyl compound, a monoglyceride and a free fatty acid.
  • the alkyl chain of the lysophosphatidyl compound (R 10 ) is of an equal length as the alkyl chains of the free fatty acid (R 9 ) and monoglyceride (one of R4, R 5 and R 6 )
  • the composition comprises a lysophosphatidyl compound of the formula I, at least one lysophosphatidyl compound of the formula II or III, and at least one a monoglyceride of the general formula IV, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IV and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I at least one lysophosphatidyl compound of the formula II or III, and at least one of a monoglyceride of the general formula IVA, a free fatty acid of the general formula V, or a combination of a monoglyceride of the general formula IVA and a free fatty acid of the general formula V.
  • the composition comprises a lysophosphatidyl compound of the formula I at least one lysophosphatidyl compound of the formula II or III, and at least one of a monoglyceride of the general formula IVC, a free fatty acid of the general formula VA, or a combination of a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition may comprise a lysophosphatidyl compound of the formula I and a lysophosphatidyl compound of the formula II, a lysophosphatidyl compound of the formula I and a lysophosphatidyl compound of the formula III or a lysophosphatidyl compound of the formula I and a lysophosphatidyl compound of the formula II and III.
  • the lysophosphatidyl compound of the formula I may be: (i) a compound of the formula I A or IB or a combination of the foregoing; (ii) a compound of the formula IC, ID, IE, IJ, IF, IG, IH, IK or a combination of the foregoing; (iii) a compound of the formula IC, ID, IE, IJ or a combination of the foregoing; (iv) a compound of the formula IF, 1 G, IH, IK or a combination of the foregoing; or (v) a compound of the formula IJ.
  • the lysophosphatidyl compound of the formula II may be: (i) a compound of the formula IIA; (ii) a compound of the formula IIB, IIC or a combination of the foregoing; (iii) a compound of the formula IID or HE; (iv) a compound of the formula IID; or (v) a compound of the formula HE
  • the lysophosphatidyl compound of the formula III may be: (i) a compound of the formula III A, IIIB or a combination of the foregoing; (ii) a compound of the formula IIIC or HID; (iii) a compound of the formula IIIC; or (iv) a compound of the formula HID.
  • the composition comprises a lysophosphatidyl compound of the formula IJ and a lysophosphatidyl compound of the formula IID, a lysophosphatidyl compound of the formula IJ and a lysophosphatidyl compound of the formula IIIC, or a lysophosphatidyl compound of the formula IJ, a lysophosphatidyl compound of the formula IID and a lysophosphatidyl compound of the formula IIIC.
  • the composition comprises, at least one lysophosphatidyl compound in the combinations as described above, a monoglyceride and a free fatty acid.
  • the alkyl chain of the lysophosphatidyl compound (R 1 ⁇ Rio or Rn) is of an equal length as the alkyl chains of the free fatty acid (R 9 ) and monoglyceride (one of R4, R and R 6 )
  • the composition comprises a lysophosphatidyl compound of the formula IJ, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IID, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IIIC, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IJ and at least one lysophosphatidyl compound of the formula IID or IIIC, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IJ and a lysophosphatidyl compound of the formula IID, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula I J and a lysophosphatidyl compound of the formula IIIC, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition comprises a lysophosphatidyl compound of the formula IJ and a lysophosphatidyl compound of the formula IID and IIIC, a monoglyceride of the general formula IVC and a free fatty acid of the general formula VA.
  • the composition may form a eutectic.
  • composition of the present disclosure is adapted for solublization of agents.
  • the composition further comprises an agent, wherein the agent is solubilized in any one of the compositions of embodiments 1-19 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 13 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 14 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 15 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 16 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 17 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 18 above.
  • the composition further comprises an agent, wherein the agent is solubilized in composition of embodiment 19 above.
  • the agent may be one that exhibits poor aqueous solubility.
  • the agent may be one at which the dose strength required for treatment of a subject is not soluble in 100 ml of aqueous solution over a pH range of 1 to 7.
  • the agent may be one at which the dose strength required for treatment of a subject is not soluble in 250 ml of aqueous solution over a pH range of 1 to 7.
  • the agent may be a BCS class II or IV agent.
  • the agent may be a BCS class III compound.
  • the composition and the agent may form a eutectic.
  • composition of the present disclosure is adapted for oral delivery of agents.
  • the composition further comprises an agent, wherein the agent is solubilized in any one of the compositions of embodiments 1-19 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 13 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 14 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 15 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 16 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 17 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 18 above and the composition is used for oral delivery of the agent to a subject.
  • the composition further comprises an agent, wherein the agent is solubilized in the compositions of embodiment 19 above and the composition is used for oral delivery of the agent to a subject.
  • the agent may be one that exhibits poor aqueous solubility.
  • the agent may be one at which the dose strength required for treatment of a subject is not soluble in 100 ml of aqueous solution over a pH range of 1 to 7.
  • the agent may be one at which the dose strength required for treatment of a subject is not soluble in 250 ml of aqueous solution over a pH range of 1 to 7.
  • the agent may be a BCS class II or IV agent.
  • the agent may be a BCS class III compound.
  • the composition and the agent may form a eutectic.
  • compositions for the oral delivery of agents may be used in combination with ancillary agents that improve the bioavailability of the composition and/or agent.
  • the ancillary agent is an inhibitor of a small intestine efflux transporter (i.e., a small intestine efflux inhibitor).
  • Representative small intestine efflux transporters include, but are not limited to, transporters of the ABC family such as MDR1 (P-glycoprotein,P- gp, ABCB1), BCRP (ABCG2), and MRP2 (ABCC2).
  • the small intestine efflux inhibitor is selected from the group consisting of verapamil, cyclosporin A, cyclosporine D, erythromycin, quinine, fluphenazine, reserpine, progesterone, tamoxifen, mitotane, annamycin, biricodar, elacridar, tariquidar and zosuquidar.
  • the ancillary agents may be a part of the composition.
  • the ancillary agent may separate from the composition.
  • the ancillary agent is administered before a composition of the present disclosure.
  • the ancillary agent is administered at the same time or after a composition of the present disclosure. Therefore, in the twenty-eighth through thirty-fifth embodiments, the composition may be administered with an ancillary agent.
  • the free (non-esterified) fatty acids and the esterified fatty acids of the monoglyceride and lysophosphatidyl components may be saturated or unsaturated. If the free fatty acids of the composition are saturated, sufficient quantities of mono-valent and divalent cations may be optionally added to form fatty acid salts. In one embodiment, the cations are present at a molar concentration of approximately one-half of the molar amount of the fatty acid. Suitable cations include sodium and calcium ions. Furthermore the lysophosphatidyl compounds and monoglyceride compounds of the present disclosure may be present as salts as well.
  • the free fatty acid and monoglyceride are present in the composition in a molar ratio of between about 2: 1 and 1 :2 (including any subrange therebetween, such as 1 : 1). In one embodiment, the free fatty acid and monoglyceride comprise from about 70 mole to 99 mole percent of the composition, with the lysophosphatidyl compound comprising from about 30 mole percent to 1 mole percent of the composition. The above mole percentages are expressed with regard to the lipid components of the composition.
  • the free fatty acid and monoglyceride are present in the composition in a molar ratio of about 2:1 and the lysophosphatidyl compound comprises from about 5 to 20 mole percent.
  • the free fatty acid and monoglyceride are present in the composition in a molar ratio of about 2: 1 and the lysophosphatidyl compound comprises from about 10 to 18 mole percent.
  • the free fatty acid and monoglyceride are of the general formula VA and IVC, respectively, and are present in the composition in a molar ratio of about 2: 1 and the lysophosphatidyl compound of the general formula IJ comprises from about 5 to 20 or 10 to 18 mole percent.
  • the ratios of the components of the composition are about 1 :4:2 lysophosphatidyl compound:monoglyceride:free fatty acid. In another embodiment, the ratios of the components of the composition are about 1 :3 :3 lysophosphatidyl compound:monoglyceride:free fatty acid. In still another embodiment, the ratios of the components of the composition are about 1 :2:4 lysophosphatidyl compound:monoglyceride:free fatty acid. In another embodiment, the ratios of the components of the composition are about 2:4:2 lysophosphatidyl compound:monoglyceride:free fatty acid.
  • compositions of the present disclosure may be used to provide oral delivery of any agent.
  • the agent is a therapeutic agent.
  • Such therapeutic agents may be used to treat and/or prevent a variety of disease or conditions, such as but not limited to, cardiac, allergic, infections or cancer related diseases or conditions.
  • the agent is fat soluble. In one embodiment, the agent is one that has a low solubility, a low permeability or a combination of the foregoing. In one embodiment, the agent is a BCS class II, class III or class IV compound.
  • BCS class II, class III and IV compounds include, but are not limited to, Acyclovir, Amiloride, Amoxicillin, Atenolol, Atropine, Bisphosphonate, Bidisomide, Captopril, Cefazolin, Cetirizine, Cimetidine, Ciprofloxacin, Cloxacillin, Dicl oxacillin, Erythromycin, Famotidine, Amphotericin, Chlorthalidone Chlorothiazide, Colistin, Furosemide, Hydrochlorothiazide, Mebendazole, Methotrexate, and Neomycin.
  • the agent is curcumin.
  • the agent may be one that exhibits poor aqueous solubility. In one embodiment, the agent may be one at which the dose strength required for treatment of a subject is not soluble in 100 ml of aqueous solution over a pH range of 1 to 7. In one embodiment, the agent may be one at which the dose strength required for treatment of a subject is not soluble in 250 ml of aqueous solution over a pH range of 1 to 7.
  • composition and the agent form a eutectic.
  • the agent is present in a molar concentration of 1 : 1 with the lysophosphatidyl compound (1 : 1 agent: lysophosphatidyl compound). In another embodiment, the agent is present in a molar concentration of less than 1 : 1 with the lysophosphatidyl compound. In still another embodiment, the agent is present in a molar concentration of 0.8: 1 with the lysophosphatidyl compound. In still another embodiment, the agent is present in a molar concentration of 0.5: 1 with the lysophosphatidyl compound. In still another embodiment, the agent is present in a molar concentration of 0.1 : 1 with the lysophosphatidyl compound.
  • An exemplary formulation includes a composition where the components are present in a molar ratio 1 :4:2: 1 lysophosphatidyl compound:monoglyceride:free fatty acid:agent.
  • An additional exemplary formulation includes a composition where the components are present in a molar ratio 1 :4:2:0.8 lysophosphatidyl compound :monoglyceride: free fatty acid:agent.
  • Still an additional exemplary formulation includes a composition where the components are present in a molar ratio 1 :4:2:0.5 lysophosphatidyl compound:monoglyceride:free fatty acid:agent.
  • the agent is present in a molar concentration of greater than 1 : 1 with the lysophosphatidyl compound (agent: lysophosphatidyl compound). In still another embodiment, the agent is present in a molar concentration of 2: 1 with the lysophosphatidyl compound. In still another embodiment, the agent is present in a molar concentration of 5 : 1 with the lysophosphatidyl compound. In still another embodiment, the agent is present in a molar concentration of 10: 1 with the lysophosphatidyl compound.
  • the composition may be any composition described herein.
  • the composition is a composition of the first to nineteenth embodiments described above, In another embodiment, the composition is a composition of the thirteenth to nineteenth embodiments described above.
  • the composition is a composition of the thirteenth embodiments described above.
  • the composition is a composition of the fourteenth embodiments described above.
  • the composition is a composition of the fifteenth embodiments described above.
  • the composition is a composition of the sixteenth embodiments described above.
  • the composition is a composition of the seventeenth embodiments described above.
  • the composition is a composition of the eighteenth embodiments described above.
  • nineteenth embodiments described above are described above.
  • compositions of the present disclosure may be prepared by a variety of methods as is known in the art.
  • the compositions of the present disclosure are prepared by weighing an appropriate amount of the individual components, in powder form, mixing the components together, dissolving the components in an aqueous buffer, sonicating the components and lyophilizing the mixture.
  • the lipid components of the mixture are present in a ratio 1 :4:2 mole percent lysophosphatidyl compound:monoglyceride:free fatty acid.
  • the sonication step occurs for 30 minutes to 5 hours at a temperature from 50 to 70 degrees.
  • the resulting lyophilized powder may be administered as a neat powder, in a matrix (for example, an edible wax or the like, or may be mixed with a liquid or food substance.
  • a matrix for example, an edible wax or the like
  • the composition may be formed into food articles, such as but not limited to, bars, powders, cookies and the like.
  • compositions of the present disclosure containing lysophosphatidyl glycerol were prepare by weighing an appropriate amount of the individual components in powder form (lysophosphatidyl compound of the formula IJ; monoglyceride of the formula IVC; and free fatty acid of the formula VA) along with curcumin and mixing the components together. The resulting composition was solubilized in water and sonicated for 60 minutes at 60 degrees. The resulting mixture was lyophilized to powder form.
  • Compositions containing lysophosphatidylcholine lysophosphatidyl compound of the formula IK; monoglyceride of the formula IVC; and free fatty acid of the formula VA
  • FIGS. 4 and 5 were prepared in the same manner.
  • the components of the mixture are present in a ratio 1 :4:2:0.8 mole percent lysophosphatidyl compound:monoglyceride:free fatty acid urcumin.
  • compositions were subject to differential scanning calorimetry. The results are shown in FIGS. 1-5.
  • FIG. 1 shows differential scanning calorimetry of a sample of curcumin, showing a phase transition at 185.12 degrees C.
  • FIG. 2 shows differential scanning calorimetry of a lipid mixture comprising lysophosphatidyl glycerol (14:0), monoglyceride (14:0) and fatty acid (14:0) (molar ratio 1 :4:2) showing a phase transition at 55.71 degrees C.
  • FIG. 1 shows differential scanning calorimetry of a sample of curcumin, showing a phase transition at 185.12 degrees C.
  • FIG. 2 shows differential scanning calorimetry of a lipid mixture comprising lysophosphatidyl glycerol (14:0), monoglyceride (14:0) and fatty acid (14:0) (molar ratio 1 :4:2) showing a phase transition at 55.71 degrees C.
  • FIG. 1 shows differential scanning calorimetry of a sample of curcumin, showing a phase transition at
  • FIG. 3 shows differential scanning calorimetry of a mixture of curcumin and a lipid mixture comprising lysophosphatidylglycerol (14:0), monoglyceride (14:0) and fatty acid (14:0) (molar ratio 1 :4:2) showing a single phase transition at 56.27 degrees C.
  • the single phase transition of the mixture indicates the composition is a eutectic.
  • FIG. 4 shows differential scanning calorimetry of a lipid mixture comprising lysophosphatidylcholine (14:0), monoglyceride (14:0) and fatty acid (14:0) (molar ratio 1 :4:2) showing a phase transition at 26.74 degrees C.
  • FIG. 5 shows differential scanning calorimetry of a mixture of curcumin and a lipid mixture comprising lysophosphatidylcholine (14:0), monoglyceride (14:0) and fatty acid (14:0) (molar ratio 1 :4:2).
  • the a lysophospatidylcholine containing composition containing curcumin showed phase transitions at 26.35 and 152.86 degrees C, indicating that the composition was not a eutectic.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2015/044501 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances Ceased WO2016025401A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020177006233A KR20170033442A (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물
KR1020227016492A KR102507657B1 (ko) 2014-08-09 2015-08-10 약물 및 기타 물질 전달용 경구 조성물
JP2017527546A JP6759203B2 (ja) 2014-08-09 2015-08-10 薬物及び他の物質の送達のための経口組成物
DK15832041.6T DK3177279T3 (da) 2014-08-09 2015-08-10 Oral sammensætning til indgivelse af medikamenter og andre substanser
AU2015301952A AU2015301952B2 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances
ES15832041T ES3033965T3 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances
CA2956960A CA2956960C (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances
EP15832041.6A EP3177279B1 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances
CN201580049486.0A CN107072967B (zh) 2014-08-09 2015-08-10 用于递送药物和其他物质的口服组合物
IL250394A IL250394B (en) 2014-08-09 2017-02-01 Oral composition for delivery of drugs and other substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462035393P 2014-08-09 2014-08-09
US62/035,393 2014-08-09

Publications (1)

Publication Number Publication Date
WO2016025401A1 true WO2016025401A1 (en) 2016-02-18

Family

ID=55304531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/044501 Ceased WO2016025401A1 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Country Status (11)

Country Link
US (3) US9872908B2 (enExample)
EP (1) EP3177279B1 (enExample)
JP (1) JP6759203B2 (enExample)
KR (2) KR102507657B1 (enExample)
CN (1) CN107072967B (enExample)
AU (1) AU2015301952B2 (enExample)
CA (1) CA2956960C (enExample)
DK (1) DK3177279T3 (enExample)
ES (1) ES3033965T3 (enExample)
IL (1) IL250394B (enExample)
WO (1) WO2016025401A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177279A4 (en) * 2014-08-09 2018-04-18 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0102324A2 (de) 1982-07-29 1984-03-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4619794A (en) * 1982-02-17 1986-10-28 Ciba-Geigy Corporation Spontaneous preparation of small unilamellar liposomes
US4619791A (en) 1981-10-21 1986-10-28 Rhone-Poulenc Chimie De Base Carbonylation of methyl acetate to acetic anhydride
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US20030077297A1 (en) 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831053B (en) * 1982-02-17 1985-03-27 Ciba Geigy Ag Lipids in aqueous phase
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH01274830A (ja) * 1988-04-28 1989-11-02 Asahi Denka Kogyo Kk 安全で且つ高度な界面活性を有する脂質組成物
JPH03127731A (ja) * 1989-10-12 1991-05-30 Yakult Honsha Co Ltd ビタミンｅの可溶化方法およびビタミンｅ製剤
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
EP2062574B1 (en) * 2006-09-08 2015-03-25 Kaneka Corporation Composition comprising reduced coenzyme q10 and lysolecithin
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619791A (en) 1981-10-21 1986-10-28 Rhone-Poulenc Chimie De Base Carbonylation of methyl acetate to acetic anhydride
US4619794A (en) * 1982-02-17 1986-10-28 Ciba-Geigy Corporation Spontaneous preparation of small unilamellar liposomes
EP0102324A2 (de) 1982-07-29 1984-03-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US20030077297A1 (en) 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177279A4 (en) * 2014-08-09 2018-04-18 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Also Published As

Publication number Publication date
KR102507657B1 (ko) 2023-03-08
KR20220070551A (ko) 2022-05-31
IL250394A0 (en) 2017-03-30
IL250394B (en) 2021-05-31
KR20170033442A (ko) 2017-03-24
AU2015301952B2 (en) 2020-12-03
CA2956960C (en) 2023-10-24
EP3177279B1 (en) 2025-06-04
CN107072967B (zh) 2021-01-12
US9872908B2 (en) 2018-01-23
CN107072967A (zh) 2017-08-18
US11510985B2 (en) 2022-11-29
DK3177279T3 (da) 2025-08-18
AU2015301952A1 (en) 2017-02-16
EP3177279A1 (en) 2017-06-14
ES3033965T3 (en) 2025-08-11
JP6759203B2 (ja) 2020-09-23
CA2956960A1 (en) 2016-02-18
JP2017524036A (ja) 2017-08-24
US20180064813A1 (en) 2018-03-08
EP3177279A4 (en) 2018-04-18
US20200188518A1 (en) 2020-06-18
US20160166699A1 (en) 2016-06-16
US10463738B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
ES2820369T3 (es) Composiciones biodegradables adecuadas para liberación controlada
WO2014144295A4 (en) Ceftolozane antibiotic compositions
WO2012095543A1 (es) Nanocápsulas con cubierta polimérica
JP2019510048A (ja) 週１回又は隔週１回の投与に適したリラグルチドの粘弾性ゲル
WO2020240514A1 (en) Stable formulations of indocyanine green
US11510985B2 (en) Oral composition for delivery of drugs and other substances
JP5811421B2 (ja) 保存効力を示す非水性油性注射用製剤
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물
KR101153250B1 (ko) 글리시리진 고농도 제제
JP2008189626A (ja) 経口用グリチルリチン可溶化製剤及びその製造方法
EP4559483A1 (en) Hyaluronic acid derivative drug composition and drug composition
CN112521322B (zh) 氨基酸类化合物及组合物及其用于治疗牙周疾病的用途
JP6204349B2 (ja) 注射剤用組成物
JP5513827B2 (ja) 外用医薬組成物
KR20140039663A (ko) 무복계면 멜록시캄 및 그 제조방법
RU2237478C2 (ru) Антимикробная фармацевтическая композиция
KR20140046499A (ko) 무복계면 암포테리신 및 그 제조방법
KR20140043572A (ko) 무복계면 이트라코나졸 및 그 제조방법
KR20140043250A (ko) 무복계면 칼슘 및 그 제조방법
KR20140043257A (ko) 무복계면 우루소데옥시콜린산 및 그 제조방법
KR20140043575A (ko) 무복계면 카페시타빈 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15832041

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2956960

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 250394

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017527546

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015301952

Country of ref document: AU

Date of ref document: 20150810

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015832041

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015832041

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177006233

Country of ref document: KR

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 2015832041

Country of ref document: EP